Cyclodextrins as pharmaceutical solubilizers

Advanced Drug Delivery Reviews

Volumn 59, Issue 7, 2007, Pages 645-666

  Brewster, Marcus E ^a   Loftsson, Thorsteinn ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b UNIVERSITY OF ICELAND   (Iceland)

Author keywords

Additives; Cyclodextrin; Phase solubility; Regulatory status; Solubility; Stability constants; Supersaturation; Toxicology

Indexed keywords

REGULATORY STATUS; STABILITY CONSTANTS; TOXICOLOGY;

DISSOLUTION; DRUG PRODUCTS; INCLUSIONS; KINETICS; SOLUBILITY; SUPERSATURATION; THERMODYNAMICS;

CYCLODEXTRINS;

8 CHLOROTHEOPHYLLINE; ALFAXALONE; ALPHA CYCLODEXTRIN; ARIPIPRAZOLE; BENEXATE; BETA CYCLODEXTRIN; CAVERJECT DUAL; CEFDITOREN PIVOXIL; CEFOTIAM; CEFOTIAM HEXETIL; CEPHALOSPORIN; CERENIA; CETRIZIN; CHLORDIAZEPOXIDE; CISAPRIDE; CLOROCIL; CYCLODEXTRIN; DEXAMETHASONE; DEXOCORT; DEXTROMETHORPHAN; DICLOFENAC; DIPHENHYDRAMINE; ESTRADIOL; FENTIAZAC; GLYCERYL TRINITRATE; GLYMESASON; HYDROCORTISONE; INDOMETACIN; IODINE; ITRACONAZOLE; LIMAPROST; MELOXICAM; MENA GARGLE; MITOEXTRA; MITOMYCIN; MITOMYCIN C; MOBITIL; NICOTINE; NICROTTE; NIMEDEX; NIMESULIDE; NITROPEN; OMEBETA; OMEPRAZOLE; OPLAMON; PIROXICAM; PIROXICAM BETA CYCLODEXTRIN; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAVASTIN; RYNATHISOL; STADA TRAVEL; TEBOROXIME TC 99M; TIAPROFENIC ACID; TRANSILLIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE; ZIPRASIDONE;

CHEMICAL MODIFICATION; COMPLEX FORMATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STRUCTURE; EQUILIBRIUM CONSTANT; HUMAN; KINETICS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SOLUBILITY; SOLUBILIZATION; STOICHIOMETRY; THERMODYNAMICS;

CYCLODEXTRINS; DRUG STABILITY; EXCIPIENTS; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; SOLUTIONS; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL;

EID: 34548134519     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.05.012     Document Type: Review

References (222)

1. Villiers A. Sur la fermentation de la fécule par l'action du ferment butyrique. Compt. Rend. Acad. Sci. 112 (1891) 536-538
2. Loftsson T., and Duchêne D. Cyclodextrins and their pharmaceutical applications. Int. J. Pharm. 329 (2007) 1-11
3. Schardinger F. Über Thermophile Bakterien aus verschiedenen Speisen und Milch, sowie über einige Umsetzungsprodukte derselben in kohlenhydrathaltigen Nährlösungen, darunter krystallisierte Polysaccharide (Dextrine) aus Stärke. Z. Unters. Nahr.- Genussm. 6 (1903) 865-880
4. Schardinger F. Bildung kristallisierter Polysaccharide (Dextrine) aus Stärkekleister durch Microben. Zentralbl. Bakteriol. Parasitenkd. Abt. II 29 (1911) 188-197
5. Freudenberg K., and Jacobi R. Über Schardinger Dextrine aus Stärke Liebigs. Ann. Chem. 518 (1935) 102-108
6. Larsen K.L. Large cyclodextrins. J. Incl. Phenom. Macrocycl. Chem. 43 (2002) 1-13
7. Ueda H., and Endo T. Large-ring cyclodextrins. In: Dodziuk H. (Ed). Cyclodextrins and their Complexes. Chemistry, analytical methods, applications (2006), Wiley-VCH Verlag, Weinheim 370-380
8. Cramer F. Einschlussverbindungen (1954), Springer-Verlag, Berlin
9. In: Uekama K. (Ed). Cyclodextrins in drug delivery. Adv. Drug Deliv. Rev. vol. 36 (1999)
10. Oguma T., and Kawamoto H. Production of cyclodextrin and its applications. Trends Glycosci. Glycotechnol. 15 (2003) 91-99
11. Uekama K., Hirayama F., and Arima H. Recent aspects of cyclodextrin-based drug delivery systems. J. Incl. Phenom. Macrocycl. Chem. 56 (2006) 3-8
12. Strickley R.G. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 21 (2004) 201-230
13. Loftsson T., Brewster M., and Masson M. Role of cyclodextrins in improving oral drug delivery. Am. J. Drug Deliv. 2 (2004) 261-275
14. Davis M.E., and Brewster M. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev., Drug Discov. 3 (2004) 1023-1035
15. Avdeef A., Bendels S., Tsinman O., Tsinman K., and Kansy M. Solubility-excipient classification gradient maps. Pharm. Res. 24 (2007) 530-545
16. Kim C., and Park J. Solubility enhancers for oral drug delivery. Am. J. Drug Deliv. 2 (2004) 113-130
17. Loftsson T., Jarho P., Masson M., and Jarvinen T. Cyclodextrins in drug delivery. Expert Opin. Drug Deliv. 2 (2005) 335-351
18. Szejtli J., and Szente L. Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins. Eur. J. Pharm. Biopharm. 61 (2005) 115-125
19. Lantz A., Rodriguez M., Wetterer S., and Armstrong D. Estimation of association constants between oral malodor components and various native and derivatized cyclodextrins. Anal. Chim. Acta 557 (2006) 184-190
20. Loftsson T., and Brewster M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 85 (1996) 1017-1025
21. Uekama K., Hirayama F., and Irie T. Cyclodextrin drug carrier systems. Chem. Rev. 98 (1998) 2045-2076
22. Szejtli J. Cyclodextrins and their inclusion complexes (1982), Akademiai Kiadó, Budapest
23. Szejtli J. Cyclodextrin Technology (1988), Kluwer Academic Publisher, Dordrecht
24. Stella V.J., and Rajewski R.A. Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. 14 (1997) 556-567
25. Frömming K.H., and Szejtli J. Cyclodextrins in pharmacy (1994), Kluwer Academic Publishers, Dordrecht
26. Winkler R.G., Fioravanti S., Ciccotti G., Margheritis C., and Villa M. Hydration of β-cyclodextrin: a molecular dynamics simulation study. J. Comput. Aided Mol. Des. 14 (2000) 659-667
27. Bone S. Dielectric studies of water clusters in cyclodextrins: relevance to the transition between slow and fast forms. J. Phys. Chem., B 110 (2006) 20609-20614
28. 1H NMR studies on the hydrogen-bonding network in mono-altro-β-cyclodextrin and its complex with adamantane-1-carboxylic acid. Carbohydr. Res. 340 (2005) 1539-1545
29. Lichtenthaler F.W., and Immel S. On the hydrophobic characteristics of cyclodextrins: computer-aided visualization of molecular lipophilicity patterns. Liebigs Ann. Chem. (1996) 27-37
30. Bender M.L., and Komiyama M. Cyclodextrin chemistry (1978), Springer-Verlag, Berlin
31. Schmid G. Cyclodextrin glycosyltransferase production; yield enhancement by overexpression of cloned genes. Tibtech 7 (1989) 244-248
32. Schmid G. Preparation and application of γ-cyclodextrin. In: Duchêne D. (Ed). New trends in cyclodextrins and derivatives, Editions de Santé: Paris (1991) 25-54
33. Sicard P.J., and Saniez M.-H. Biosynthesis of cycloglycosyltransferase and obtention of enzymatic reaction products. In: Duchêne D. (Ed). Cyclodextrins and their industrial uses, Editions de Santé: Paris (1987) 77-103
34. Rajewski R.A., and Stella V.J. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. 85 (1996) 1142-1168
35. Irie T., and Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 86 (1997) 147-162
36. Thompson D.O. Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. Crit. Rev. Ther. Drug Carr. Syst. 14 (1997) 1-104
37. Evaluation of Certain Food Additives and Contaminants. WHO Technical Report Series vol. 909 (2002) 41-42
38. Lina B.A.R., and Bär A. Subchronic oral toxicity studies with α-cyclodextrin in rats. Regul. Toxicol. Pharmacol. 39 (2004) S14-S26
39. Lina B.A.R., and Bär A. Subchronic (13-week) oral toxicity study of α-cyclodextrin in dogs. Regul. Toxicol. Pharmacol. 39 (2004) S27-S33
40. Bellringer M.E., Smith T.G., Read R., Gopinath C., and Oliver P. β-Cyclodextrin: 52-week toxicity studies in the rat and dog. Food Chem. Toxicol. (1995) 367-376
41. Munro I.C., Newberne P.M., Young R.R., and Bär A. Safety assessment of γ-cyclodextrin. Regul. Toxicol. Pharmacol. 39 Suppl. 1 (2004) S3-S13
42. Koutsou G.A., Storey D.M., and Bär A. Gastrointestinal tolerance of γ-cyclodextrin in humans. Food Addit. Contam. 16 (1999) 313-317
43. Gould S., and Scott R.C. 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): a toxicology review. Food Chem. Toxicol. 43 (2005) 1451-1459
44. M.E. Brewster, C. Mackie, A. Lampo, M. Noppe, T. Loftsson, The use of solubilizing excipients and approaches to generate toxicology vehicles for contemporary drug pipelines, in: P. Augustijns and M.E. Brewster (Eds.), Solvent systems and their selection in pharmaceutics and biopharmaceutics, American Association of Pharmaceutical Scientists and Springer: New York, (2007), pp. 221-256.
45. Physician's Desk Reference. Fifty-seventh Edition. (2003), Medical Economics Company, Montvale, NJ
46. Toxicological data. BETA W7 M1.8 (1997), Wacker-Chemie, München
47. Uekama K. Design and evaluation of cyclodextrin-based drug formulation. Chem. Pharm. Bull. 52 (2004) 900-915
48. Antlsperger G., and Schmid G. Toxicological comparison of cyclodextrins. In: Szejtli J., and Szente L. (Eds). Proceedings of the eighth international symposium on cyclodextrins. Budapest, Hungary, March 32 - April 2, 1996 (1996), Kluwer Acad. Pub., Dordrecht 149-155
49. Hirayama F., and Uekama K. Cyclodextrin-based controlled release systems. Adv. Drug Deliv. Rev. 36 (1999) 125-141
50. Challa R., Ahuja A., Ali J., and Khar R. Cyclodextrin in drug delivery: an updated review. AAPS PharmSciTech 6 (2005) E329-E357
51. Vromans H., Eissens A., and Lerk C. Mechanism of dissolution of drug-cyclodextrin complexes. A pragmatic approach. Acta Pharm. Technol. 35 (1989) 250-255
52. Amidon G.L., Lennernås H., Shah V.P., and Crison J.R. Theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
53. Dressman J.B., Amidon G., Reppas C., and Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15 (1998) 11-22
54. Yu L., Amidon G., Polli J., Zhao H., Mehta M., Conner D., Shah V.P., Lesko L., Chen M., Lee V.L., and Hussain A.S. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res. 19 (2002) 921-925
55. Loftsson T. Cyclodextrins and the biopharmaceutical classification system of drugs. J. Incl. Phenom. Macrocycl. Chem. 44 (2002) 63-67
56. Pitha J., Hoshino T., Torres-Labandeira J., and Irie T. Preparation of drug-hydroxypropyl cyclodextrin complexes by a method using ethanol or aqueous ammonium hydroxide as cosolubilizers. Int. J. Pharm. 80 (1992) 253-258
57. Pitha J., and Hoshino T. Effect of ethanol on formation of inclusion complexes of hydroxypropyl cyclodextrin with testosterone or with methyl orange. Int. J. Pharm. 80 (1992) 243-251
58. Stella V., Rao V., Zannou E., and Zia V. Mechanisms of drug release from cyclodextrin complexes. Adv. Drug Deliv. Rev. 36 (1999) 3-16
59. Connors K.A. Population characteristics of cyclodextrin complex stabilities in aqueous solution. J. Pharm. Sci. 84 (1995) 843-848
60. Connors K.A. The stability of cyclodextrin complexes in solution. Chem. Rev. 97 (1997) 1325-1357
61. Rao V.M., and Stella V.J. When can cyclodextrins be considered for solubilizing purposes?. J. Pharm. Sci. 92 (2003) 927-932
62. Aoyama Y., Otsuki J., Nagai Y., Kobayashi K., and Toi H. Host-guest complexation of oligosaccharides: interaction of maltodextrins with hydrophobic fluorescence probes in water. Tetrahedron Lett. 33 (1992) 3775-3778
63. In: Riley C.M., Rytting J.H., and Kral M.A. (Eds). Takeru Higuchi, a Memorial Tribute. Equilibria and Thermodynamics vol. 3 (1991), Allen Press, Lawrence (Kansas)
64. Loftsson T., Fridriksdottir H., and Gudmundsdottir T.K. The effect of water-soluble polymers on aqueous solubility of drugs. Int. J. Pharm. 127 (1996) 293-296
65. Tomasik P., and Schilling C.H. Complexes of starch with inorganic guests. In: Horton D. (Ed). Advances in carbohydrate chemistry and biochemistry (1998), Academic Press, San Diego 263-343
66. Tomasik P., and Schilling C.H. Complexes of starch with organic guests. In: Horton D. (Ed). Advances in carbohydrate chemistry and biochemistry (1998), Academic Press, San Diego 345-426
67. Gabelica V., Galic N., and De Pauw E. On the specificity of cyclodextrin complexes detected by electrospray mass spectrometry. J. Am. Soc. Mass Spectrom. 13 (2002) 946-953
68. Correia I., Bezzenine N., Ronzani N., Platzer N., Beloeil J.-C., and Doan B.-T. Study of inclusion complexes of acridine with β- and (2,6-di-O-methyl)-β-cyclodextrin by use of solubility diagrams and NMR spectroscopy. J. Phys. Org. Chem. 15 (2002) 647-659
69. Andronati S.A., Shapiro Y.E., Yakubovskaya L.N., Gorbatyuk V.Y., Andronati K.S., and Krasnoschekaya S.P. Inclusion compounds of psychotropic agents and cyclodextrins. J. Incl. Phenom. Macrocycl. Chem. 24 (1996) 175-186
70. Loftsson T., Magnúsdóttir A., Másson M., and Sigurjónsdóttir J.F. Self-association and cyclodextrin solubilization of drugs. J. Pharm. Sci. 91 (2002) 2307-2316
71. Loftsson T., Másson M., and Brewster M.E. Self-association of cyclodextrins and cyclodextrin complexes. J. Pharm. Sci. 93 (2004) 1091-1099
72. Chadha R., Kashid N., and Saini A. Account of analytical techniques employed for the determination of thermodynamics of inclusion complexation of drugs with cyclodextrins. J. Sci. Ind. Res. 63 (2004) 211-229
73. Higuchi T., and Connons K.A. In: Reilly C.N. (Ed). Advances in Analytical Chemistry and Instrumentation vol. 4 (1965), Wiley-Interscience, New York 117-212
74. Connons K.A. Measurement of cyclodextrin complex stability constants. In: Szejtli J., and Osa T. (Eds). Comprehensive Supramolecular Chemistry vol. 3 (1996), Elsevier, Oxford, UK 205-241
75. Brewster M., and Loftsson T. Complexation - use of cyclodextrins to improve pharmaceutical properties of intramuscular formulations. In: Gupta P., and Brazeau G. (Eds). Injectable drug development - techniques to reduce pain and irritation (1999), Interpharm Press, Buffalo Grove, IL 307-336
76. Loftsson T., Hreinsdóttir D., and Másson M. Evaluation of cyclodextrin solubilization of drugs. Int. J. Pharm. 302 (2005) 18-28
77. Higuchi T., and Kristiansen H. Binding specificity between small organic solutes in aqueous solution: classification of some solutes into two groups according to binding tendencies. J. Pharm. Sci. 59 (1970) 1601-1608
78. Peeters J., Neeskens P., Tollenaere J., Van Remoortere P., and Brewster M.E. Characterization of the interaction of 2-hydroxypropyl-β-cyclodextrin with itraconazole at pH 2, 4 and 7. J. Pharm. Sci. 91 (2002) 1414-1422
79. Pourmokhtar M., and Jacobson G. Enhanced stability of sulfamethazole and trimethoprim against oxidation using hydroxypropyl-β-cyclodextrin. Pharmazie 60 (2005) 837-839
80. Chen C., Chen F., Wu A., Hsu H., Kang J., and Cheng H. Effect of hydroxypropyl-β-cyclodextrin on the solubility, photostability and in-vivo permeability of alkannin/shikonin enantiomers. Int. J. Pharm. 141 (1996) 171-178
81. Bekers O., Beijnen J., Otagiri M., Bult A., and Underberg W. Inclusion complexation of doxorubicin and daunorubicin with cyclodextrins. J. Pharm. Biomed. Anal. 8 (1990) 671-674
82. Brewster M., Loftsson T., Estes K., Lin J., and Bodor N. Effect of various cyclodextrins on solution stability and dissolution rate of doxorubicin hydrochloride. Int. J. Pharm. 79 (1991) 289-299
83. Cervero M., and Mendicuti F. Inclusion complexes of dimethyl 2,6-naphthalenedicarboxylate with α- and β-cyclodextrins in aqueous medium: thermodynamics and molecular mechanics study. J. Phys. Chem., B 104 (2000) 1572-1580
84. Mohanty J., Bhasikuttan A., Nau W., and Pal H. Host-guest complexation of neutral red with macrocyclic host molecules: contrasting pKa shifts and binding affinities for cucurbit[7]uril and β-cyclodextrin. J. Phys. Chem., B 110 (2006) 5132-5138
85. Yang C., Liu L., Mu T., and Guo Q. The performance of the Benesi-Hildebrand method in measuring the binding constants of the cyclodextrin complexation. Anal. Sci. 16 (2000) 537-539
86. Crane N., Mayrhofer R., Betts T., and Baker G. Cyclodextrin inclusion complexes with a solvatochrome fluorescent probe. J. Chem. Educ. 79 (2002) 1261-1263
87. Abdel-Shafi A. Spectroscopic studies on the inclusion complex of 2-naphtol-6-sulfonate with β-cyclodextrin. Spectrochim. Acta, Part A: Mol. Biomol. Spectrosc. 66A (2007) 732-738
88. Schneider H. Supermolecular Chemistry. 36. NMR spectroscopy and molecular-mechanics calculations in supermolecular chemistry. Rec. Trav. Chem. 112 (1993) 412-419
89. Ganza-Gonzalez A., Vila-Jato J., Anguiano-Igea S., Otero-Espinar F., and Blanco-Mendez J. A proton nuclear magnetic resonance study of the inclusion of naproxen with β-cyclodextrin. Int. J. Pharm. 106 (1994) 179-185
90. Piel G., Llabres G., Evrard B., Van Hees T., de Hassonville S., and Delattre L. A nuclear magnetic resonance study of the miconazole-β-cyclodextrin inclusion complex in an acidic medium: determination of the structure and stability constant. STP Pharm. Sci. 11 (2001) 235-238
91. Masson M., Sigurjonsdottir J., Jonsdottir S., and Loftsson T. Estimation of 19F-NMR as a tool for investigation of drug-cyclodextrin complexes. Drug Dev. Ind. Pharm. 29 (2003) 107-112
92. Polyakov N., Leshina T., Konovalova T., Hand E., and Kispert L. Inclusion complexes of carotenoids with cyclodextrins: 1H-NMR, EPR and optical studies. Free Radic. Biol. Med. 36 (2004) 872-880
93. Hofler T., and Wenz G. Determination of binding energies between cyclodextrins and aromatic guest molecules by calorimetry. J. Incl. Phenom. Macrocycl. Chem. 25 (1996) 81-84
94. Wenz G., Hofler T., Wehrle S., and Schneider M. Inclusion of pharmaceutical drugs in cyclodextrins as measured by titration microcalorimetry. Polym. Prepr. 39 (1998) 202-203
95. Li S., and Connors K. Complex formation between α-cyclodextrin and 4-substituted phenols studies by potentiometric and competitive spectrophotometric methods. J. Pharm. Sci. 72 (1983) 1333-1338
96. Davies D., Deary M., and Wealleans D. Stability constants of α-cyclodextrin complexes of para-substituted aromatic ketones in aqueous solution. J. Chem. Soc., Perkin Trans. 2 (1998) 193-196
97. Masson M., Sigurdardottir B., Matthiasson K., and Loftsson T. Investigation of drug-cyclodextrin complexes by a phase-distribution method: some theoretical and practical consideration. Chem. Pharm. Bull. 53 (2005) 958-964
98. Moeder C., O'Brian T., Thompson R., and Bicker G. Determination of stoichiometric coefficients and apparent stability constants for α- and β-CD complexes of terpenes using reversed-phase liquid chromatography. J. Chromatogr., A 736 (1996) 1-9
99. Loukas Y., Antoniadou-Vyza E., Papadaki-Valiraki A., and Machera K. γ-Cyclodextrin complex of a new organophosphate insecticide. Determination of stability constant with HPLC. J. Agric. Food Chem. 42 (1994) 944-948
100. Durham D., and Liang H. Molecular modeling of the inclusion complexes between β-cyclodextrin and (R)/(S)-methylphenobarbitone and its application to HPLC. Chirality 6 (1994) 240-244
101. Fukahori T., Nishikawa S., and Yamaguchi K. Ultrasonic relaxation due to inclusion complex of amino acid by β-cyclodextrin in aqueous solution. J. Acoust. Soc. Am. 115 (2004) 2325-2330
102. Cirri M., Maestrelli F., Orlandini S., Furlanetto S., Pinzauti S., and Mura P. Determination of stability constant values of flurbiprofen-cyclodextrin complexes using different techniques. J. Pharm. Biomed. Anal. 37 (2005) 995-1002
103. Landy D., Tetart F., Truabt E., Blach P., Fourmentin S., and Surpateanu G. Development of a competitive continuous variation plot for the determination of inclusion compound stoichiometry. J. Incl. Phenom. Macrocycl. Chem. 57 (2007) 409-413
104. Loukas Y. Measurement of molecular association in drug: cyclodextrin inclusion complexes with improved 1H NMR studies. J. Pharm. Pharmacol. 49 (1997) 944-948
105. In: Sinko P.J. (Ed). Martin's Physical Pharmacy and Pharmaceutical Sciences (2006), Lippincott Williams & Wilkins, Philadelphia
106. Ross P.D., and Rekharsky M.V. Thermodynamics of hydrogen bond and hydrophobic interactions in cyclodextrin complexes. Biophys. J. 71 (1996) 2144-2154
107. Tong W.-Q., Lach J.L., Chin T.-F., and Guillory J.K. Microcalorimetric investigation of the complexation between 2-hydroxypropyl-β-cyclodextrin and amine drugs with diphenylmethyl functionality. J. Pharm. Biomed. Anal. 9 (1991) 1139-1146
108. Gelb R.I., Schwartz L.M., Radeos M., and Laufer D.A. Cycloamylose complexation of organic anions. J. Phys. Chem. 87 (1982) 3349-3354
109. Gelb R.I., Schwartz L.M., Cardelino B., Fuhrman H.S., Johnson R.F., and Laufer D.F. Binding mechanisms in cyclohexaamylose complexes. J. Am. Chem. Soc. 103 (1981) 1750-1757
110. Kurihara M., Hirayama F., Uekama K., and Yamasaki M. Improvement of some pharmaceutical properties of cloprost by β- and γ-cyclodextrin complexation. J. Incl. Phenom. Mol. Recognit. Chem. 8 (1990) 363-373
111. Matsuyama K., El-Gizawy S., and Perrin J.H. Thermodynamics of binding of aromatic amino acids to α-, β- and γ-cyclodextrin. Drug Dev. Ind. Pharm. 13 (1987) 2687-2691
112. Alvira E., Garcia J., and Mayoral J. Factors influencing β-cyclodextrin inclusion complex formation. Recent Res. Dev. Chem. Phys. 1 (2000) 89-100
113. Marques H. Application of cyclodextrins. Thermodynamic aspects of cyclodextrin complexes. Rev. Port. Farm. 44 (1994) 85-96
114. Liu L., and Guo Q. Novel prediction for the driving force and guest orientation in the complexation of α- and β-cyclodextrin with benzene derivatives. J. Phys. Chem., B 103 (1999) 3461-3467
115. Pinjari R., Joshi K., and Gejji S. Molecular electrostatic potentials and hydrogen bonding in α-, β-, and γ-cyclodextrins. J. Phys. Chem., A 110 (2006) 13073-13080
116. Bergeron R.J. Cycloamylose-substrate binding. In: Attwood J.L., Davies J.E.D., and MacNicol D.D. (Eds). Inclusion Compounds (1984), Academic Press, London 391-443
117. Liu L., and Guo Q. The driving forces in the inclusion complexation of cyclodextrins. J. Incl. Phenom. Macrocycl. Chem. 42 (2002) 1-14
118. Liu L., Li W., and Guo Q. Regression analysis for the host-guest interaction of β-cyclodextrin with mono- and 1, 4-disubstituted benzenes. J. Incl. Phenom. Macrocycl. Chem. 34 (1999) 413-419
119. Magnusdottir A., Masson M., and Loftsson T. Self-association and cyclodextrin solubilization of NSAID's. J. Incl. Phenom. Macrocycl. Chem. 44 (2002) 213-218
120. Loftsson T., Matthiasson K., and Masson M. The effect of organic salts on the cyclodextrin solubilization of drugs. Int. J. Pharm. 262 (2003) 101-107
121. Loftsson T., Másson M., and Sigurjónsdóttir J.F. Methods to enhance the complexation efficiency of cyclodextrins. STP Pharm. Sci. 9 (1999) 237-242
122. Loftsson T., and Másson M. The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs. J. Drug Del. Sci. Tech. 14 (2004) 35-43
123. Jug M., Becirevic-Lacan M., Cetina-Cizmek B., and Horvat M. Hydroxy methylcellulose microspheres with piroxicam and piroxicam-hydroxypropyl-β-cyclodextrin inclusion complex. Pharmazie 59 (2004) 686-691
124. Ribeiro L., Ferreira D., and Veiga F. Physicochemical investigations on the effects of water-soluble polymers on vinpocetine complexation with β-cyclodextrin and its sulfobutyl ether derivative in solution and solid state. Eur. J. Pharm. Sci. 20 (2003) 253-266
125. Cirri M., Maestrelli F., Corti G., and Mura P. Simultaneous effect of cyclodextrin complexation, pH and hydrophilic polymers on naproxen solubilization. J. Pharm. Biomed. Anal. 42 (2006) 126-131
126. Valero M., Carrillo C., and Rodriguez L. Ternary naproxen:β-cyclodextrin:polyethylene glycol complex formation. Int. J. Pharm. 265 (2003) 141-149
127. Jug M., and Becirevic-Lacan M. Multicomponent complexes of piroxicam with cyclodextrin and hydroxypropyl methylcellulose. Drug Dev. Ind. Pharm. 30 (2004) 1051-1060
128. Ribeiro L., Loftsson T., Ferreira D., and Veiga F. Investigation and physicochemical characterization of vinpocetine-sulfobutyl ether β-cyclodextrin binary and ternary complexes. Chem. Pharm. Bull. 51 (2003) 914-922
129. Krishnamoorthy R., and Mitra A.K. Complexation of weak acids and basis with cyclodextrins: Effects of substrate ionization on the estimation and interpretation of association constants. Int. J. Pharm. Adv. 1 (1996) 330-343
130. Redenti E., Szente L., and Szejtli J. Cyclodextrin complexes of salts of acidic drugs. Thermodynamic properties, structural features, and pharmaceutical applications. J. Pharm. Sci. 90 (2001) 979-986
131. Redenti E., Szente L., and Szejtli J. Drug/cyclodextrin/hydroxy acid multicomponent systems. Properties and pharmaceutical applications. J. Pharm. Sci. 89 (2000) 1-8
132. Ribeiro L., Carvalho R., Ferreira D., and Veiga F. Multicomponent complex formation between vinpocetine, cyclodextrins, tartaric acid and water-soluble polymers monitored by NMR and solubility studies. Eur. J. Pharm. Sci. 24 (2005) 1-13
133. Loftsson T., Sigur{eth}sson H.H., Másson M., and Schipper N. Preparation of solid drug/cyclodextrin complexes of acidic and basic drugs. Pharmazie 59 (2004) 25-29
134. Mura P., Maestrelli F., and Cirri M. Ternary systems of naproxen with hydroxypropyl-β-cyclodextrin and amino acids. Int. J. Pharm. 260 (2003) 293-302
135. Li P., Tabibi E., and Yalkowsky S.H. Combined effect of complexation and pH on solubilization. J. Pharm. Sci. 87 (1998) 1535-1537
136. Loftsson T., Hreinsdóttir D., and Másson M. The complexation efficiency. J. Incl. Phenom. Macrocycl. Chem. 57 (2007) 545-552
137. Usui F., Maeda K., Kusai A., Nishimura K., and Yamamoto K. Inhibitory effects of water-soluble polymers on precipitation of RS-8359. Int. J. Pharm. 154 (1997) 59-66
138. Attwood D., and Florence A.T. Surfactant systems. Their chemistry, pharmacy and biology (1983), Chapmann and Hall, London 361-365
139. Myers D. Surfactant Science and Technology (1988), VCH Publishers, New York 142-145
140. Malmsten M. Surfactants and polymers in drug delivery (2002), Marcel Dekker, New York
141. Loftsson T., and Fri{eth}riksdóttir H. The effect of water-soluble polymers on the aqueous solubility and complexing abilities of β-cyclodextrin. Int. J. Pharm. 163 (1998) 115-121
142. Valero M., Esteban B., Peláez R., and Rodríguez L.J. Naproxen:hydroxypropyl-β-cyclodextrin:polyvinylpyrrolidone ternary complex formation. J. Incl. Phenom. Macrocycl. Chem. 48 (2004) 157-163
143. Yamakawa T., and Nishimura S. Liquid formulation of a novel non-fluorinated topical quinolone, T-3912, utilizing the synergic solubilizing effect of the combined use of magnesium ions and hydroxypropyl-β-cyclodextrin. J. Control. Release 86 (2003) 101-113
144. Harada A. Design and construction of supramolecular architectures consisting of cyclodextrins and polymers. Adv. Polym. Sci. 133 (1997) 141-191
145. Torres-Labandeira J.J., Davignon P., and Pitha J. Oversaturated solutions of drug in hydroxypropylcyclodextrins: parenteral preparation of pancratistatin. J. Pharm. Sci. 80 (1990) 384-386
146. Brewster M., Neeskens P., and Peeters J. Solubilization of itraconazole as a function of cyclodextrin structural space. J. Incl. Phenom. Macrocycl. Chem. 57 (2007) 561-566
147. Xiang T., and Anderson B. Stable supersaturated aqueous solution of Silatecan 7-t-butyldimethylsilyl-10-hydroxycamptothecin via chemical conversion in the presence of a chemically modified β-cyclodextrin. Pharm. Res. 19 (2002) 1215-1222
148. Wang Z., Hirayama F., Ikegami K., and Uekama K. Release characteristics of nifedipine from 2-hydroxypropyl-β-cyclodextrin complex during storage and its modification of hybridizing polyvinylpyrrolidone K-30. Chem. Pharm. Bull. 41 (1993) 1822-1826
149. Uekama K., Ikegami K., Weng Z., Horiuchi Y., and Hirayama F. Inhibitory effect of 2-hydroxypropyl-β-cyclodextrin on crystal-growth of nifedipine during storage: superior dissolution and oral bioavailability compared with polyvinylpyrrolidone K-30. J. Pharm. Pharmacol. 44 (1992) 73-78
150. Jaconson J., Bjerregaard S., and Pedersen M. Cyclodextrin inclusion complexes of antimycotics intended to act in the oral cavity - drug supersaturation, toxicity to TR166 cells and release from a delivery system. Eur. J. Pharm. Biopharm. 48 (1999) 217-224
151. Castillo J., Palomo-Canales J., Garcis J., Lastres J., Bolas F., and Torrado J. Preparation and characterization of albendazole β-cyclodextrin complexes. Drug Dev. Ind. Pharm. 25 (1999) 1241
152. Pedersen M., Bjerregaard S., Jaconson J., and Sorensen A. A genuine clotrimazole γ-cyclodextrin inclusion complex-isolation, antimycotic activity, toxicity and unusual dissolution rate. Int. J. Pharm. 176 (1998) 121-131
153. Pedersen M., Bjerregaard S., Jacobson J., Larsen A., and Sorensen A. An econazole β-cyclodextrin inclusion complex: an unusual dissolution rate, supersaturation and biological efficacy example. Int. J. Pharm. 165 (1998) 57-68
154. Pedersen M., Jacobson J., and Sorensen A. Cyclodextrin inclusion complexes of miconazole and econazole - isolation, toxicity on human cells and confirmation of a new interpretation of the drug supersaturation phenomenon. Drug Dev. Ind. Pharm. 25 (1999) 463-470
155. Leichtman M., Rolland H., Wuthrich P., and Guy R. Impact of antinucleants on transdermal delivery of testosterone from a spray. J. Pharm. Sci. 96 (2007) 84-92
156. Dias M., Raghavan S., Pellett M., and Hadgraft J. The effect of β-cyclodextrin on the permeation of diclofenac from supersaturated solutions. Int. J. Pharm. 263 (2003) 173-181
157. Iervolino M., Cappello B., Raghavan S., and Hadgraft J. Penetration enhancement of ibuprofen from supersaturated solutions through human skin. Int. J. Pharm. 212 (2001) 131-141
158. Iervolino M., Raghavan S., and Hadgraft J. Membrane penetration enhancement of ibuprofen using supersaturation. Int. J. Pharm. 198 (2000) 229-238
159. Macie C., and Grant D. Crystal growth in pharmaceutical formulation. Pharm. Intl. (1986) 233-237
160. Raghvan S., Trividic A., Davis A., and Hadgraft J. Crystallization of hydrocortisone acetate: influence of polymers. Int. J. Pharm. 212 (2001) 213-221
161. Raghavan S., Schuessel K., Davis A., and Hadgraft J. Formation and stabilization of triclosan colloidal suspension using supersaturated systems. Int. J. Pharm. 261 (2003) 153-158
162. Gao P., Guyton M., Huang T., Bauer J., Stefanski K., and Lu Q. Enhanced oral bioavailability of a poorly water-soluble drug PNU-91325 by supersaturable formulations. Drug Dev. Ind. Pharm. 30 (2004) 221-229
163. Terayama H., Inada K., Nakayama H., Yasueda S., and Esumi K. Preparation of stable aqueous suspension of a hydrophobic drug with polymers. Colloids Surf., B Biointerfaces 39 (2004) 159-164
164. Simonelli A., Mehta S., and Higuchi W. Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone. J. Pharm. Sci. 59 (1970) 633-638
165. Rodriguez-Hornedo N., and Murphy D. Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. J. Pharm. Sci. 88 (1999) 651-660
166. Yokoi Y., Yonemochi E., and Terada K. Effect of sugar esters and hydroxypropyl methylcellulose on the physicochemical stability of amorphous pivoxil in aqueous suspension. Int. J. Pharm. 290 (2005) 91-99
167. Pedersen M. The bioavailability difference between genuine cyclodextrin inclusion complexes and freeze-dried or ground drug cyclodextrin samples may be due to supersaturation differences. Drug Dev. Ind. Pharm. 23 (1997) 331-335
168. Lipinski C., Lombardo F., Dominy B., and Feeney P. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997) 3-25
169. Lipinski C. Avoiding investment in doomed drugs. Curr. Drug Discov. 1 (2001) 17-19
170. Prentis R., Lis Y., and Walker S. Pharmaceutical innovation by seven UK-owned pharmaceutical companies. Br. J. Clin. Pharmacol. 2 (1988) 387-396
171. Kola I., and Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev., Drug Discov. 2 (2004) 711-715
172. Liu R. Water-insoluble drug formulation (2000), CO Interpharm Press, Englewood
173. Abdoh A., El-Barghouthi M., Zughul M., Davies J., and Badwah A. Changes in the conformational structure, microscopic and macroscopic pKa's of meloxicam on complexation with natural and modified cyclodextrins. Pharmazie 62 (2007) 55-59
174. Beni S., Szakacs Z., Csernak O., Barcza L., and Noszal B. Cyclodextrin/imatinib complexation: binding mode and charge dependent stabilities. Eur. J. Pharm. Sci. 30 (2007) 167-174
175. Morales C., Abrami P., Paula E., Braga A., and Fraceto L. Study of the interaction between S(-)bupivacaine and 2-hydroxypropyl-β-cyclodextrin. Int. J. Pharm. 331 (2007) 99-106
176. Figeiras A., Sarraguca M., Carvalho R., Pais A., and Veiga F. Interaction of omeprazole with a methylated derivative of β-cyclodextrin: phase solubility, NMR spectroscopy and molecular simulations. Pharm. Res. 24 (2007) 377-389
177. Al Omari M., Zughul M., Davies J., and Badwan A. Sidenafil/cyclodextrin complexation: stability constants, thermodynamics and guest-host interactions probed by 1H NMR and molecular modeling studies. J. Pharm. Biomed. Anal. 41 (2006) 857-865
178. Lahiani-Skiba M., Barbot C., Bounoure F., Joudieh S., and Skiba M. Solubility and dissolution rate of progesterone-cyclodextrin-polymer systems. Drug Dev. Ind. Pharm. 32 (2006) 1043-1058
179. Lee P., Han J., Song T., Sung J., Kwon O., Song S., and Chung Y. Physicochemical characterization and bioavailability of a novel intestinal metabolite of ginseng saponin (IH901) complexes with β-cyclodextrin. Int. J. Pharm. 316 (2007) 29-36
180. Uzqueda M., Martin C., Zornoza A., Sanchez M., Matinez-Oharriz M., and Velaz I. Characterization of complexes between naftifine and cyclodextrins in solution and in the solid state. Pharm. Res. 23 (2006) 980-988
181. Ventura C., Giannone I., Musumeci T., Pignatello R., Ragni L., Landolfi C., Milanese C., Paolino D., and Puglisi G. Physico-chemical characterization of disoxaril-dimethyl-β-cyclodextrin inclusion complex and in vitro permeation studies. Eur. J. Med. Chem. 41 (2006) 233-240
182. Perry C., Charman S., Prankerd R., Chiu F., Scalon M., Chalmers D., and Charman W. The binding interaction of synthetic ozonide antimalarials with natural and modified β-cyclodextrins. J. Pharm. Sci. 95 (2006) 146-158
183. Cappello B., Di Maio C., Iervolino M., and Miro A. Improvement of solubility and stability of valsartan by hydroxypropyl-β-cyclodextrin. J. Incl. Phenom. Macrocycl. Chem. 54 (2006) 289-294
184. Torne J., and Vavia P. Inclusion complexation of anti-HIV drug with β-cyclodextrin. J. Incl. Phenom. Macrocycl. Chem. 56 (2006) 253-259
185. Shen Y., Ying W., Yang S., and Wu L. Determination of the inclusion complex between gossypol and β-cyclodextrin. Spectrochim. Acta, Part A 65A (2006) 169-172
186. Al Omari M., Zughul M., Davies J., and Badwan A. Effect of buffer species on the inclusion complexation of acidic drug celecoxib with cyclodextrin in solution. J. Incl. Phenom. Macrocycl. Chem. 55 (2006) 247-254
187. Jadhav G., Patel A., Vavia P., Malde A., and Coutinho E. Interaction of valdecoxib with β-cyclodextrin: experimental and molecular modeling studies. J. Incl. Phenom. Macrocycl. Chem. 56 (2006) 261-273
188. Pinto L., Fraceto L., Santana M., Pertinhez T., Junior S., and Paula E. Physico-chemical characterization of benzocaine-β-cyclodextrin inclusion complexes. J. Pharm. Biomed. Anal. 39 (2005) 956-963
189. Tommasini S., Calabro M., Stancanelli R., Donato P., Costa C., Catania S., Villari V., Ficarra P., and Ficarra R. The inclusion complexes of hesperetin and its 7-rhamnoglucoside with (2-hydroxypropyl)-β-cyclodextrin. J. Pharm. Biomed. Anal. 39 (2005) 572-580
190. Zheng Y., Haworth I., Zuo Z., Chow M., and Chow A. Physicochemical and structural characterization of quercetin-β-cyclodextrin complexes. J. Pharm. Sci. 94 (2005) 1079-1089
191. Yap K., Liu X., Thenmozhiyal J., and Ho P. Characterization of the 1,3-cis-retinoic acid/cyclodextrin inclusion complexes by phase solubility, photostability, physicochemical and computational analysis. Eur. J. Pharm. Sci. 25 (2005) 49-56
192. Rajendrakumar K., Madhusudan S., and Pralhad T. Cyclodextrin complexes of valdecoxib: properties and anti-inflammatory activity in the rat. Eur. J. Pharm. Biopharm. 60 (2005) 39-46
193. Larsen K., Aachmann F., Wimmer R., Stella V., and Kjolner U. Phase solubility and structure of the inclusion complexes of prednisolone and 6α-methyl prednisolone with various cyclodextrins. J. Pharm. Sci. 94 (2005) 507-515
194. Loftsson T., Ossurardottir I., Thorsteinsson T., Duan M., and Masson M. Cyclodextrin solubilization of the antibacterial agents triclosan and triclocarban: effect of ionization and polymers. J. Incl. Phenom. Macrocycl. Chem. 53 (2005) 109-117
195. El-Barghouthi M., Masoud N., Al-Kafawein J., Zughul M., and Badwan A. Host-guest interactions of risperidone with natural and modified cyclodextrins: phase-solubility, thermodynamics and molecular modeling studies. J. Incl. Phenom. Macrocycl. Chem. 53 (2005) 15-22
196. Sinha V., Anitha R., Ghosh S., Nanda A., and Kumria R. Complexation of celecoxib with β-cyclodextrin: characterization of the interaction in solution and in solid state. J. Pharm. Sci. 94 (2005) 676-687
197. Calabro M., Tommasini S., Donato P., Raneri D., Stancanelli R., Ficarra P., Ficarra R., Costa C., Cantania S., Rustichelli C., and Gamberini G. Effects of α- and β-cyclodextrin complexation on the physico-chemical properties and antioxidant activity of some 3-hydroxyflavones. J. Pharm. Biomed. Anal. 35 (2004) 365-377
198. Mukne A., and Nagarsenker M. Triamterene-β-cyclodextrin systems: preparation, characterization and in vivo evaluation. AAPS PharmSciTech 5 (2004) 1-9 (Article 19)
199. Sætern A., Nguyen N., Bauer-Brandl A., and Brandl M. Effect of hydroxypropyl-β-cyclodextrin-complexation and pH on the solubility of camptothecin. Int. J. Pharm. 284 (2004) 61-68
200. Yanez C., Salazar R., Nunez-Vergara L., and Squella J. Spectrophotometric and electrochemical study of the inclusion complex between β-cyclodextrin and furnidipine. J. Pharm. Biomed. Anal. 35 (2004) 51-56
201. Rawat S., and Jain S. Solubility enhancement of celecoxib using β-cyclodextrin inclusion complexes. Eur. J. Pharm. Biopharm. 57 (2004) 263-267
202. Castro-Hermida J., Gomez-Couso H., Ares-Mazas M., Gonzales-Bedia M., Castaneda-Cancio N., Otero-Espinar F., and Blanco-Mendez J. Anticryptosporidial activity of furan derivative G1 and its inclusion complex with β-cyclodextrin. J. Pharm. Sci. 93 (2004) 197-206
203. Yamamura H., Rekharsky M., Ishihara Y., Kawai M., and Inoue Y. Factors controlling the complex architecture of native and modified cyclodextrins with dipeptide (Z-Glu-Tyr) studies by microcalorimetry and NMR spectroscopy: critical effects of peripheral bis-trimethylamination and cavity size. J. Am. Chem. Soc. 126 (2004) 14224-14233
204. Aki H., Niiya T., Iwase Y., Kawasaki Y., Kumai K., and Kimura T. Multimodal inclusion complexes of ampicillin with β-cyclodextrin in aqueous solution. Thermochim. Acta 416 (2004) 87-92
205. Rajendrakumar K., Pralhad T., and Madhusudan S. Comparative study on co-ground products of rofecoxib with β-cyclodextrin and its sulfobutyl ether-7 derivative in solution and in the solid state. J. Incl. Phenom. Macrocycl. Chem. 49 (2004) 259-266
206. Vlachou M., and Papaioannou G. Preparation and characterization of the inclusion complex of furosemide with hydroxypropyl-β-cyclodextrin. J. Biomater. Appl. 17 (2003) 197-206
207. Koontz J., and Marcy J. Formation of natamycin: cyclodextrin inclusion complexes and their characterization. J. Agric. Food Chem. 51 (2003) 7106-7110
208. Waleczek K., Marques H., Hempel B., and Schmidt P. Phase solubility studies of pure (-)-α-bisbolol and chamomile essential oil with β-cyclodextrin. Eur. J. Pharm. Biopharm. 55 (2003) 247-251
209. Liu X., Thenmozhiyal J., Chan S., and Ho P. Inclusion of acitretine into cyclodextrin: phase solubility, photostability and physicochemical characterization. J. Pharm. Sci. 92 (2003) 2449-2457
210. Holvoet C., Plaizier-Vercammen J., Vander Heyden Y., Gabriels M., and Camu F. Preparation and in-vivo release rate of fentanyl-cyclodextrin complexes for prolonged action in epidural analgesia. Int. J. Pharm. 265 (2003) 13-26
211. Rawat S., and Jain S. Rofecoxib-β-cyclodextrin inclusion complex for solubility enhancement. Pharmazie 58 (2003) 639-641
212. Illapakurthy A., Sabnis Y., Avery B., Avery M., and Wyandt C. Interaction of artemisinin and its related compounds with hydroxypropyl-β-cyclodextrin in solution state: experimental and molecular-modeling studies. J. Pharm. Sci. 92 (2003) 649-655
213. Taneri F., Guneri T., Aigner Z., and Kata M. Influence of cyclodextrin complexation on the physicochemical and biopharmaceutical properties of ketoconazole. J. Incl. Phenom. Macrocycl. Chem. 47 (2003) 15-23
214. Chen F., Wu A., and Chen C. Inclusion complex of carprofen with hydroxypropyl-β-cyclodextrin. J. Incl. Phenom. Macrocycl. Chem. 46 (2003) 111-115
215. Barbato F., Cappello B., La Rotonda M., Miro A., and Quaglia F. Diclofenac/β-cyclodextrin binary systems: a study in solution and in the solid state. J. Incl. Phenom. Macrocycl. Chem. 46 (2003) 179-185
216. Tavornvipas S., Arima H., Hirayama F., Uekama K., Ishiguro T., Oka M., Hamayasu K., and Hashimoto H. Some pharmaceutical properties of a new branched cyclodextrin, 6-O-α-(4-O-α-d-glucuronyl)-d-glucosyl-β-cyclodextrin. J. Incl. Phenom. Macrocycl. Chem. 44 (2002) 391-394
217. Tavornvipas S., Hirayama F., Arima H., Uekama K., Ishiguro T., Oka M., Hamayasu K., and Hashimoto H. 6-O-α-(4-O-α-d-glucoronyl-d-glucosyl-β-cyclodextrin: solubilizing ability and some cellular effects. Int. J. Pharm. 249 (2002) 199-209
218. De Bie A.T.H.J., van Ommen B., and Bär A. Disposition of 14C-γ-cyclodextrin in germ-free and conventional rats. Regul. Toxicol. Pharmacol. 27 (1998) 150-158
219. Van Ommen B., De Bie A.T.H.J., and Bär A. Disposition of 14C-α-cyclodextrin in germ-free and conventional rats. Regul. Toxicol. Pharmacol. 39 (2004) S57-S66
220. Antlsperger G. New aspects in cyclodextrin toxicology. In: Hedges A.R. (Ed). Minutes of the sixth international symposium on cyclodextrins, Editions de Santé: Paris (1992) 277-283
221. Matsuda K., Mera Y., Segawa Y., Uchida I., Yokomine A., and Takagi K. Acute toxicity study of γ-cyclodextrin (γ-CD) in mice and rats. Ogo Yakuri (Pharmacometrics), 26 (1983) 287-291
222. In: Moffat A.C., Osselton M.D., and Widdop B. (Eds). Clarke's Analysis of drugs and poisons. 3rd ed. vol. 2 (2004), Pharmaceutical Press, London